Home
Activity Overview
Related Articles
Christopher Bunick, MD, PhD, Previews RAD 2025: Raising the Bar in Atopic Dermatitis Care
Discover how the RAD conference in Nashville enhances atopic dermatitis care, featuring expert insights and patient-focused strategies for clinicians.
Combination of Baricitinib and Phototherapy in Adults With Active Vitiligo
This randomized clinical trial assesses the efficacy and adverse events of baricitinib combined with narrowband UV-B in adults with severe, active, nonsegmental vitiligo.
Pigmentary Disorders Exchange Symposium 2025 | Chicago, IL
The 3rd Annual Pigmentary Disorders Exchange Symposium will bring back together world-renowned dermatology experts who will spend two full days diving deep into pigmentary disorders…
Upadacitinib Outpaces Dupilumab in Rapid AD Symptom Control
Discover how upadacitinib outperforms dupilumab in providing rapid itch relief for moderate-to-severe atopic dermatitis in a recent AAD study.
Managing Wound Risks in Patients on TKIs
Explore how tyrosine kinase inhibitors hinder wound healing, revealing critical insights for clinicians in dermatology and oncology.
JID May 2025 Cover: Three distinct pH zones in the stratum corneum of the skin
skin barrier, stratum corneum, pH, homeostasis, desquamationIntravital confocal image of dorsal skin sample from Asprv1Venus-mCherry/+ hairless mice. These m…
The Role of Patient-Centered Communication in Alopecia Areata Treatment, Part 1
In this first episode of a two-part podcast, Victoria Barbosa, MD, introduces the foundational principles of patient-centered communication in the context of alopecia areata. She…
Exclusive: Outgoing AAD President Seemal Desai, MD, FAAD, on the 3 Issues That Will Shape Dermatology in 2025 (& Beyond)
Dermatology undergoes rapid transformation with new therapies, but faces challenges in payment reform, certification awareness, and balancing technology with patient care.
Poly-l-Lysine Biovectors with Vitamins A and C Effective for Atopic Dermatitis
DLQI score reduced by 61.8% and SCORAD score reduced by 41.8% in patients after 28 days of treatment.